Navigation Links
Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
Date:4/29/2008

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Preliminary results were released today from a late-stage clinical trial of Rituxan (rituximab) for the treatment of lupus. The study did not meet its primary or secondary endpoints of clinically reducing the severity of SLE (systemic lupus erythematosus) in people with moderate disease.

The findings are initial results from a Phase II/III study conducted by Genentech, Inc., known as the EXPLORER study. Rituxan is approved by the U.S. Food and Drug Administration for the treatment of non-Hodgkin's lymphoma, and was more recently approved, in combination with methotrexate, to treat rheumatoid arthritis. More detailed findings from the trial are expected to be presented at a medical conference this fall.

Following is a statement about the study results from Sandra C. Raymond, President & CEO of the Lupus Foundation of America:

"Demonstrating the impact of a treatment in a lupus clinical trial can be difficult, as lupus manifests itself differently in different people, and can increase and decrease in severity from one day to another. So while these new results are disappointing, they are not necessarily surprising.

"People with lupus have been waiting for a new treatment for nearly 45 years while suffering from this disabling and sometimes life-threatening disease. But it's important to remember that there are a variety of promising therapies in the near-term pipeline - including an ongoing study of Rituxan for the treatment of lupus nephritis (kidney disease). That study assesses Rituxan's potential in a focused subset of lupus patients with a highly objective outcome. Thus, we remain optimistic that we are coming ever closer to new and better treatments for lupus.

"Lupus patients have suffered without a new treatment for more than four decades. For this reason, we are grateful to the companies that are searching for new lupus treatments. The millions of people who battle lupus with their families every day have waited long enough."

About Lupus

Lupus is the result of an unbalanced immune system that can become destructive to any major organ or tissue in the body. Lupus is unpredictable and potentially fatal, yet no satisfactory treatment or cure exists. Its health consequences may include heart attacks, strokes, seizures, or sudden organ failure. Current treatments are immune-suppressing agents, which have toxic side effects, increasing risks for infections and other bodily damage. The LFA estimates that more than 1.5 million Americans have some form of lupus.

Although lupus can strike any person at any age, nine of 10 people with lupus are women of childbearing age (ages 15-45). Lupus is two to three times more common among women of color, including African Americans, Hispanics, Native Americans and Asians.

About the Lupus Foundation of America

The LFA is the nation's foremost nonprofit voluntary health organization dedicated to finding the causes of and cure for lupus, and providing support, services, and hope to all people affected by lupus. The LFA and its network of nearly 300 chapters, branches, and support groups conduct programs of research, education, and advocacy.


'/>"/>
SOURCE Lupus Foundation of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
2. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
3. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
4. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
9. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
10. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
11. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):